Michael Siekman counsels clients of all sizes in the biotechnology and pharmaceutical industries on a range of intellectual property matters, including patent prosecution and portfolio strategy, licensing, post-grant proceedings, and litigation. His over 25 years of experience has included developing patent portfolios for several pioneering biotechnologies—most recently in the area of synthetic biology—and leveraging those portfolios to meet his clients’ business goals.

Michael has successfully run and argued several ex parte and inter partes cases before the Patent Trial and Appeal Board (PTAB), and he has coordinated several successful oppositions before the European Patent Office. He is also regularly involved in litigations for clients he represents—though a good part of his practice involves trying to avoid such contested matters, keeping in mind his clients’ business goals at all times.

Michael’s extensive transactional experience includes settlement agreements from the dozens of contested cases he has handled before the PTAB since the mid-1990s; strategic collaboration agreements between clients and partners; IP-related aspects of mergers, acquisitions, IPOs and other financings; and large licensing programs run by clients for portfolios licensed to many companies.

Michael’s prosecution advice is heavily informed by his experience with Hatch-Waxman litigation for generic drugs and post-grant matters for biosimilars, and he advises clients about these issues regularly.

As a parent of a child with Type 1 diabetes, Michael particularly enjoys representing biotechnology and medical device companies in that field.

Michael served as Co-Chair of the firm’s Biotechnology Group from 2009-2016.

Client testimonial:
"Michael defines what it means to get quality work. It is timely and at a reasonable cost."
Client testimonial:
"Michael is really willing to do what is right for us and not dictate to us how we should do something."


  • Lead counsel in two IPRs defending a patent covering an antibody product with annual sales of $100 million for longtime client BTG International Inc. Obtained termination of IPR with parallel ITC proceeding and denial of institution of second IPR.
  • Lead counsel in four IPRs defending four Cold Spring Harbor Laboratory patents relating to short hairpin RNA (shRNA). Obtained denial of institution of all four IPRs, preserving Cold Spring Harbor’s robust and widely licensed shRNA patent portfolio. 
  • Lead counsel in interference for Dyax against key competitor. Invalidated competitor’s patent and obtained patent to same invention by proving 11 months of diligence.
  • Defended IP diligence on biotechnology client in acquisition valued at $6.5 billion.
  • Obtained seminal patents in the fields of gene therapy, phage display, yeast display, and the transgenic production of proteins in animals.
  • Prosecutes one of the most widely licensed biotechnology patent portfolios, with projected milestones and royalties of several hundred million dollars per year.
  • Directed the patent prosecution for a life-saving biologic, including a successful appeal to the Court of Appeals for the Federal Circuit.
  • Obtained Patent Term Extensions and coordinated Supplementary Protection Certificate strategies for several clients.

  • American Intellectual Property Law Association–PTAB Trial Committee
  • Boston Patent Law Association
  • Juvenile Diabetes Research Foundation (JDRF)–IP Task Force (2010); Diabetes Innovation Fund Board of Directors (2011); New England Chapter Board of Directors (2013-2016); Nominating and Governance Committee (2018-)

Michael received a National Science Foundation Award in college and served as Articles Editor for the Boston University Journal of Science & Technology Law in law school.

He has also been repeatedly named to the Massachusetts Super Lawyers list for his work in the field of intellectual property law.

A former collegiate soccer player, Michael has coached his children’s teams for over 20 seasons.

Expand All

Michael Siekman counsels clients of all sizes in the biotechnology and pharmaceutical industries on a range of intellectual property matters, including patent prosecution and portfolio strategy, licensing, post-grant proceedings, and litigation. His over 25 years of experience has included developing patent portfolios for several pioneering biotechnologies—most recently in the area of synthetic biology—and leveraging those portfolios to meet his clients’ business goals.

Michael has successfully run and argued several ex parte and inter partes cases before the Patent Trial and Appeal Board (PTAB), and he has coordinated several successful oppositions before the European Patent Office. He is also regularly involved in litigations for clients he represents—though a good part of his practice involves trying to avoid such contested matters, keeping in mind his clients’ business goals at all times.

Michael’s extensive transactional experience includes settlement agreements from the dozens of contested cases he has handled before the PTAB since the mid-1990s; strategic collaboration agreements between clients and partners; IP-related aspects of mergers, acquisitions, IPOs and other financings; and large licensing programs run by clients for portfolios licensed to many companies.

Michael’s prosecution advice is heavily informed by his experience with Hatch-Waxman litigation for generic drugs and post-grant matters for biosimilars, and he advises clients about these issues regularly.

As a parent of a child with Type 1 diabetes, Michael particularly enjoys representing biotechnology and medical device companies in that field.

Michael served as Co-Chair of the firm’s Biotechnology Group from 2009-2016.

Client testimonial:
"Michael defines what it means to get quality work. It is timely and at a reasonable cost."
Client testimonial:
"Michael is really willing to do what is right for us and not dictate to us how we should do something."


  • Lead counsel in two IPRs defending a patent covering an antibody product with annual sales of $100 million for longtime client BTG International Inc. Obtained termination of IPR with parallel ITC proceeding and denial of institution of second IPR.
  • Lead counsel in four IPRs defending four Cold Spring Harbor Laboratory patents relating to short hairpin RNA (shRNA). Obtained denial of institution of all four IPRs, preserving Cold Spring Harbor’s robust and widely licensed shRNA patent portfolio. 
  • Lead counsel in interference for Dyax against key competitor. Invalidated competitor’s patent and obtained patent to same invention by proving 11 months of diligence.
  • Defended IP diligence on biotechnology client in acquisition valued at $6.5 billion.
  • Obtained seminal patents in the fields of gene therapy, phage display, yeast display, and the transgenic production of proteins in animals.
  • Prosecutes one of the most widely licensed biotechnology patent portfolios, with projected milestones and royalties of several hundred million dollars per year.
  • Directed the patent prosecution for a life-saving biologic, including a successful appeal to the Court of Appeals for the Federal Circuit.
  • Obtained Patent Term Extensions and coordinated Supplementary Protection Certificate strategies for several clients.

  • American Intellectual Property Law Association–PTAB Trial Committee
  • Boston Patent Law Association
  • Juvenile Diabetes Research Foundation (JDRF)–IP Task Force (2010); Diabetes Innovation Fund Board of Directors (2011); New England Chapter Board of Directors (2013-2016); Nominating and Governance Committee (2018-)

Michael received a National Science Foundation Award in college and served as Articles Editor for the Boston University Journal of Science & Technology Law in law school.

He has also been repeatedly named to the Massachusetts Super Lawyers list for his work in the field of intellectual property law.

A former collegiate soccer player, Michael has coached his children’s teams for over 20 seasons.